Literature DB >> 30390059

Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma.

Parastoo B Dahi1,2, Hillard M Lazarus3, Craig S Sauter4,5, Sergio A Giralt4,5.   

Abstract

High-dose chemotherapy and autologous hematopoietic cell transplantation (HDT-AHCT) remains an effective therapy in lymphoma. Over the past several decades, HDT with BEAM (carmustine, etoposide, cytarabine, and melphalan) and CBV (cyclophosphamide, carmustine, and etoposide) have been the most frequently used preparatory regimens for AHCT in Hodgkin (HL) and non-Hodgkin lymphoma (NHL). This article reviews alternative combination conditioning regimens, as well as novel transplant strategies that have been developed, to reduce transplant-related toxicity while maintaining or improving efficacy. These data demonstrate that incorporation of maintenance therapy posttransplant might be the best way to improve outcomes.

Entities:  

Mesh：

Year:  2018        PMID： 30390059      PMCID： PMC9062884          DOI： 10.1038/s41409-018-0378-z

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.174


  113 in total

1.  Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).

Authors:  H M Lazarus; F R Loberiza; M J Zhang; J O Armitage; K K Ballen; A Bashey; B J Bolwell; L J Burns; C O Freytes; R P Gale; J Gibson; R H Herzig; C F LeMaistre; D Marks; J Mason; A M Miller; G A Milone; S Pavlovsky; D E Reece; J D Rizzo; K van Besien; J M Vose; M M Horowitz
Journal:  Bone Marrow Transplant       Date:  2001-02       Impact factor: 5.483

2.  Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group.

Authors:  A Sureda; R Arranz; A Iriondo; E Carreras; J J Lahuerta; J García-Conde; I Jarque; M D Caballero; C Ferrà; A López; J García-Laraña; R Cabrera; D Carrera; M D Ruiz-Romero; A León; J Rifón; J Díaz-Mediavilla; R Mataix; M Morey; J M Moraleda; A Altés; A López-Guillermo; J de la Serna; J M Fernández-Rañada; J Sierra; E Conde
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

3.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.

Authors:  D C Linch; D Winfield; A H Goldstone; D Moir; B Hancock; A McMillan; R Chopra; D Milligan; G V Hudson
Journal:  Lancet       Date:  1993-04-24       Impact factor: 79.321

4.  Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience.

Authors:  Ilhami Berber; Mehmet Ali Erkurt; Ilknur Nizam; Mustafa Koroglu; Emin Kaya; Irfan Kuku; Harika Gozukara Bag
Journal:  Int J Clin Exp Med       Date:  2015-09-15

5.  Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.

Authors:  Sigal Grisariu; Michael Y Shapira; Reuven Or; Batia Avni
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-02-15

6.  Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up.

Authors:  M Kornacker; J Stumm; C Pott; S Dietrich; S Süssmilch; M Hensel; M Nickelsen; M Witzens-Harig; M Kneba; N Schmitz; A D Ho; P Dreger
Journal:  Ann Oncol       Date:  2009-01-29       Impact factor: 32.976

7.  Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation.

Authors:  D Villa; M Crump; A Keating; T Panzarella; B Feng; J Kuruvilla
Journal:  Ann Oncol       Date:  2013-02-20       Impact factor: 32.976

8.  Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies.

Authors:  E Frei; S A Holden; R Gonin; D J Waxman; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma.

Authors:  Henry C Fung; Patrick Stiff; Jeff Schriber; Amir Toor; Eileen Smith; Tulio Rodriguez; Amrita Krishnan; Arturo Molina; David Smith; Barbara Ivers; Neil Kogut; Leslie Popplewell; Roberto Rodriguez; George Somlo; Stephen J Forman; Auayporn Nademanee
Journal:  Biol Blood Marrow Transplant       Date:  2007-03-23       Impact factor: 5.742

10.  Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.

Authors:  Lloyd E Damon; Jeffrey L Johnson; Donna Niedzwiecki; Bruce D Cheson; David D Hurd; Nancy L Bartlett; Ann S Lacasce; Kristie A Blum; John C Byrd; Michael Kelly; Wendy Stock; Charles A Linker; George P Canellos
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544
View more
  2 in total

1.  Population Pharmacokinetics of Melphalan in a Large Cohort of Autologous and Allogeneic Hematopoietic Cell Transplantation Recipients: Towards Individualized Dosing Regimens.

Authors:  Gunjan L Shah; Jaap Jan Boelens; Dean Carlow; Andrew Lin; Ryan Schofield; Nancy Cruz Sitner; Anna Alperovich; Josel Ruiz; Anthony Proli; Parastoo Dahi; Roni Tamari; Sergio A Giralt; Michael Scordo; Rick Admiraal
Journal:  Clin Pharmacokinet       Date:  2021-12-02       Impact factor: 5.577

2.  Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation.

Authors:  Saro H Armenian; Aleksi Iukuridze; Jennifer Berano Teh; Kristen Mascarenhas; Alex Herrera; Jeannine S McCune; Jasmine M Zain; Sogol Mostoufi-Moab; Shana McCormack; Thomas P Slavin; Jessica M Scott; Lee W Jones; Can-Lan Sun; Stephen J Forman; F Lennie Wong; Ryotaro Nakamura
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-03-25       Impact factor: 12.910
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.